Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14181454 | 1.00 | IDO1 (0.46) | IDO1TYRSLC6A2SLC6A3EPHX1 | |
| SCHEMBL18519491 | 0.89 | ADRB2 (0.42) | SLC6A2SLC6A3EPHX1TP53TSHR | |
| SCHEMBL2269394 | 0.82 | CYP3A4 (0.42) | TP53TSHRTAAR1 | |
| SCHEMBL242931 | 0.82 | CYP3A4 (0.42) | TP53TSHRTAAR1 | |
| SCHEMBL9498462 | 0.82 | CYP3A4 (0.42) | TP53TSHRTAAR1 | |
| SCHEMBL18459574 | 0.81 | IDO1 (0.46) | IDO1TYRSLC6A2SLC6A3EPHX1 | |
| SCHEMBL1972358 | 0.80 | TAAR1 (0.40) | IDO1SLC6A2SLC6A3TP53TSHR | |
| SCHEMBL9503518 | 0.80 | CA2 (0.41) | SLC6A2SLC6A3TP53TSHRTAAR1 | |
| SCHEMBL6495729 | 0.80 | SLC6A4 (0.59) | IDO1SLC6A2SLC6A3TAAR1CYP2C19 | |
| SCHEMBL2266844 | 0.80 | TAAR1 (0.40) | IDO1SLC6A2SLC6A3TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| EP-3052121-B1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | UNIV LELAND STANFORD JUNIOR (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11008366-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2017044633-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2012173846-A2 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012021875-A1 | PEPTIDOMIMETIC MACROCYCLES WITH TRIAZOLE LINKERS | AILERON THERAPEUTICS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | ILK, EPCAM, MMP8 | IDO1 1338/4885TYR 1334/4885SLC6A2 4273/4885 |
| US-11008366-B2 | Peptidomimetic macrocycles | GLP1R, PROKR1, VIP | IDO1 1962/4885TYR 1641/4885SLC6A2 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.